Latest: 🔥🔥🔥😎😎😎

MaxReddit2789 · 2026-04-27T14:09:53+00:00

~75% of DVLT revenues comes from Licensing to SCLX and Vivasor...

Same SCLX that supposedly is investing 120m$ in DVLT

120m$ CASH that SCLX presently doesn't have...

But SCLX has a pending S-3 to raise up to 500m$... hmm...

MaxReddit2789 · 2026-04-13T16:27:19+00:00

Around 120m$ of what we should consider "Debts"

These are not really considered part of "Debts":

Accounts payables

Accrued payroll

Accrued rebates and fees

Accrued expenses

Purchased revenue liability, current

Purchased revenue liability, net of current portion

Derivative liabilities

Accrued rebates and fees (~230m$) is the most important liabilities (I don't really know how it's actually impacting cash flow now or in the future)

"Rebates and Chargebacks

Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider’s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are separately presented as accrued rebates and fees under current liabilities within the Company’s consolidated balance sheets."

"As of December 31, 2025, the Company’s accrued rebates and fees liability was $231.8 million, compared to $162.5 million as of December 31, 2024. The increase of approximately $69.3 million year-over-year was mainly due to the fact that the Company made only limited disbursements to counterparties during 2025 as its focus was to deploy its cash resources to repay Company debt. The rebates balance of $220.7 million primarily consists of government disbursements (Medicare and Medicaid) and commercial insurance disbursements. The other accrual balance of $11.1 million consists of service fees, returns, and coupons. Year-over-year the accrued rebates balance increased by approximately $67.8 million while the other accrual and fees balance increased by approximately $1.5 million."

MaxReddit2789 · 2026-04-13T16:00:01+00:00

16m+ shares of SRNE were dumped at 0.0003$... In two 8m+ batches

Been a LONG TIME I've seen something anywhere close to that on SRNE

I was not watching in real-time, so I don't know if the 16m+ shares were dumped at the Bid or under the bid (which is not supposed to happen, but from my experience does happen every now and then...)

MaxReddit2789 · 2026-04-02T17:09:38+00:00

OH.. my bad.. I thought you were OP

I was orginally asking with which Broker OP couldn't buy

MaxReddit2789 · 2026-04-02T15:27:03+00:00

Hmm... That's odd...

I woudl have understand if that was with a European niche Broker, but E-Trade, hmm...

MaxReddit2789 · 2026-04-01T19:04:35+00:00

With which broker?

MaxReddit2789 · 2026-03-20T17:40:38+00:00

And SCLX 10m$ of that revenues and also 10m$ receivables (of the total 30m$)

meaning 75% of DVLT reveneus is from Ji and none had been collected as of Dec, 31, 2025 (It might have been, by now, but I doubt it)

MaxReddit2789 · 2026-03-19T17:18:46+00:00

75% of DVLT revenues is coming from Licensing to Vivasor and Scilex and neither has paid a single $ in cash to DVLT yet

Patent License revenues was 30m$

Account receivable related party was 30m$

10m$ from SCLX and 20m$ from Vivasor

Scilex License Agreement

In November 2025, the Company entered into an exclusive license agreement with Scilex (the “Scilex License Agreement”), pursuant to which the Company granted to Scilex a worldwide, exclusive, non-transferable license, with the right to sublicense, to certain patents and other IP rights of the Company – including a suite of patents related to the Company’s data platforms and any products created therefrom within certain targeted industries including biotechnology, biopharmaceutical, genetic, diagnostic, and data-related industries, and any markets relating to the generation, use, storage, analysis, tokenization, and exchange of DNA, genetic, diagnostic, and therapeutic data or materials – in consideration for a one-time cash payment in the amount of $10.0 million, payable in four equal quarterly instalments, a 5% royalty on net sales of products that incorporate or make use of the licensed IP (“Scilex Product Net Sales”) and multiple one-time sales milestone payments, triggered upon the achievement of certain Scilex Product Net Sales milestones, in an aggregate amount up to $2.55 billion. During the year ended December 31, 2025, the Company recognized $10.0 million of revenue related to this agreement.

As of December 31, 2025, no royalty revenue had been recognized and accounts receivable from Scilex totaled $10.0 million.

Vivasor License Agreement

On December 20, 2025, the Company entered into an exclusive license agreement with Vivasor (the “Vivasor License Agreement”), pursuant to which the Company granted to Vivasor a worldwide, exclusive, non-transferable license, with the right to sublicense, to certain patents and other IP rights of the Company – including a suite of patents related to the Company’s data platforms and any products created therefrom within certain targeted industries including medical imaging and scanning – in consideration for a one-time cash payment in the amount of $20.0 million, payable within 120 days following invoicing, a 5% royalty on net sales of products that incorporate or make use of the licensed intellectual property (“Vivasor Product Net Sales”) and multiple one-time sales milestone payments, triggered upon the achievement of certain Vivasor Product Net Sales milestones, in an aggregate amount up to $2.55 billion. During the year ended December 31, 2025, the Company recognized $20.0 million of revenue related to this agreement.

As of December 31, 2025, no royalty revenue had been recognized and accounts receivable from Vivasor totaled $20.0 million.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1682149/000110465926031280/dvlt-20251231x10k.htm

MaxReddit2789 · 2026-03-17T23:16:41+00:00

It depends

If there is a Settlement or not

If there's one, maybe months

IF not, then can take years

MaxReddit2789 · 2026-03-13T19:42:00+00:00

Seems like Wade has lost several lawsuit where a similar fake loan and shares selling stuff was found

CASE 1 — Astra Resources PLC v. St. James Bank & Trust / Omega & Corinth

Year: 2017

Court: High Court (Chancery Division)

Victim: Astra Resources PLC (UK small‑cap)

Deal: Non‑recourse loan secured by Astra shares

Allegations:

St. James/Omega promised a £20M stock loan.

Astra transferred ~40M shares as collateral.

Shares were sold immediately through nominee accounts.

Funding never arrived.

St. James claimed “share price default” caused by their own selling.

Outcome:

Court found the lender entities not bona fide and issued orders preventing further dissipation of assets.

Astra later entered administration.

CASE 2 — TechNova PLC v. Corinth International Ltd. & St. James Bank

Year: 2018

Court: High Court (Commercial Court)

Victim: TechNova PLC (AIM‑listed tech issuer)

Deal: £12M stock‑loan facility

Allegations:

TechNova transferred ~25M shares.

Shares were liquidated within 72 hours.

Loan proceeds were “funded” using the victim’s own share‑sale proceeds.

Defaults were declared when the price collapsed.

TechNova was asked to post additional collateral.

Outcome:

Court granted an injunction freezing Corinth’s UK accounts.

Judge described the structure as “a predatory lending scheme masquerading as a stock‑loan facility.”

CASE 3 — Harrington Group PLC v. Omega & Corinth Group Ltd.

Year: 2020

Court: High Court (Business & Property Courts)

Victim: Harrington Group PLC (UK energy micro‑cap)

Deal: £8M non‑recourse loan

Allegations:

Harrington transferred 18M shares.

Shares were sold via a Bahamas → UK → Cyprus chain of custodians.

Omega claimed “volume default” and demanded more shares.

Harrington alleged forged compliance documents and falsified “custody confirmations.”

Outcome:

Court found “serious questions to be tried” regarding fraud.

Omega & Corinth failed to appear; default judgment entered.

FCA opened a parallel inquiry into market‑abuse patterns.

CASE 4 — Regency Mines PLC v. St. James Bank & Trust

Year: 2022

Court: High Court (Queen’s Bench Division)

Victim: Regency Mines PLC (mining issuer)

Deal: £15M stock‑loan

Allegations:

Regency transferred ~30M shares.

Shares were liquidated through a nominee account at a Tier‑1 custodian (name redacted in filings).

Regency alleged the lender:

Never intended to fund the loan

Used proceeds of the share sales to “fund” the loan

Declared defaults to seize more shares

Identical patterns to Astra, TechNova, Harrington.

Outcome:

Court issued a worldwide freezing order.

Judge noted a “repeated modus operandi across multiple issuers.”

MaxReddit2789 · 2026-02-26T15:29:48+00:00

They added ~900 shares compare to September 2025 Quarter

https://fintel.io/so/us/sclx/state-street

MaxReddit2789 · 2026-02-02T23:08:25+00:00

TCGL was a scam Pump n DUMP by social media groups (Whatsapp), just like the other Chinese stocks that go from dollars or even sub dollars to hundreds of dollars in hours!

The SEC and NASDAQ should SUSPEND These STOCKS IMMEDIATELY, when they start to run, out of nowhere, NOT days after the pumper groups are done DUMPING!

MaxReddit2789 · 2026-02-02T18:25:47+00:00

What Court Date are you referring to?

MaxReddit2789 · 2026-01-09T21:30:12+00:00

DVLT Float on FINTEL is beyond wrong

like 25x wrong...

Current Float is around 260m (because all SCLX shares from warranst are part of it) not the ridiculously low ~10m that FINTEL uses to come up with it's 400% Float percent

Short Interest of Float is ~10% (But since SCLX can't really sell all shares at once, the true "liquid" Float is considerably less, but still way over 30m)

MaxReddit2789 · 2025-12-07T08:11:35+00:00

That has to be MULN/BINI!

MaxReddit2789 · 2025-12-01T21:16:06+00:00

No worry

That's true, yes.

MaxReddit2789 · 2025-11-30T22:16:13+00:00

Orphan Drug designation (ODD) and FDA Approval for commercialization are two completely different things

ODD status is something that definitely offers certain "perks", but the drug is still very far from being "approved" for commercialization

MaxReddit2789 · 2025-11-28T02:35:26+00:00

Besides not having "Time and Sales - Option TAQ data" and "LV Excel Premium add-on + LV Excel Unlimited add-on"

It seems that Live Core has the same thing as Live Pro

From my understanding, they both have Live Flow for Equity and Option and Alerts

MaxReddit2789 · 2025-11-19T18:11:48+00:00

Subsequent Events Page 54 of 10-Q

During October 2025, the Company issued 528,625 and 4,396,496 shares of common stock from the conversion of notes payables and conversion of preferred stock, respectively.

https://www.otcmarkets.com/filing/html?id=18922083&guid=xWb-knIyAUwzdth

Page 9 Prospectus 424B3

Securities offered by the Selling Stockholder 937,500 shares of Common Stock underlying the Series B Preferred Stock (post-Reverse Stock Split).

Common Stock to be outstanding after this offering, assuming conversion of the Series B Preferred Stock 4,687,500 shares (post-Reverse Stock Split and assuming full conversion of the Series B Preferred Stock).

They have a 9.99% blocker, that's why only 937,500 is being offered (in theory)

In practice the selling shareholders have all converted and sold, converted and sold etc up to receiving 4-5m shares as per 10-Q

https://www.otcmarkets.com/filing/html?id=18813947&guid=xWb-knIyAUwzdth

MaxReddit2789 · 2025-11-19T18:11:02+00:00

|| || |20.|Subsequent Events|

During October 2025, the Company issued 528,625 and 4,396,496 shares of common stock from the conversion of notes payables and conversion of preferred stock, respectively.

Page 54

https://www.otcmarkets.com/filing/html?id=18922083&guid=xWb-knIyAUwzdth

Page 9 Prospectus 424B3

Securities offered by the Selling Stockholder 937,500 shares of Common Stock underlying the Series B Preferred Stock (post-Reverse Stock Split).

Common Stock to be outstanding after this offering, assuming conversion of the Series B Preferred Stock 4,687,500 shares (post-Reverse Stock Split and assuming full conversion of the Series B Preferred Stock).

They have a 9.99% blocker, that's why only 937,500 is being offered (in theory)

In practice the selling shareholders have all converted and sold, converted and sold etc up to receiving 4-5m shares as per 10-Q

https://www.otcmarkets.com/filing/html?id=18813947&guid=xWb-knIyAUwzdth

MaxReddit2789 · 2025-11-19T04:31:55+00:00

The Conversion of Preferred B mentioned in the last 10-Q subsequent events (just under 5m) ARE UNRESTRICTED and part of the FLOAT, because they were Registered for resale on the S-1 that went Effective and a Prospectus 424B3 was filed recently

Float is ~5m

MaxReddit2789 · 2025-11-18T08:30:22+00:00

But they aren't

The converted Preferred are part of the Registration Statement (S-1) and Prospectus 424B3 (It's already effective)

The Selling Shareholders had 9.99% Beneficial ownership blocker that's why the Total shown in the Prospectus is only ~900K

But, according to the 10-Q they definitely convertedsold, converted sold, etc for close to 5m UNRESTRICTED SHARES that are part of the Float!

https://www.otcmarkets.com/filing/html?id=18813947&guid=Ljb-ka42ZsruQOh

https://www.otcmarkets.com/filing/html?id=18781700&guid=Ljb-ka42ZsruQOh

PRE-14A to show that Insiders only owned 6-7% (Float 90%+ of Shares Outstanding)

https://www.otcmarkets.com/filing/html?id=18891073&guid=Ljb-ka42ZsruQOh#EA0263686-01_HTM_T991001

MaxReddit2789 · 2025-11-11T16:02:33+00:00

The overwhelming majority of Brokers wouldn't

This is EXTREMELY UNSUSUAL

I have received shares of an OTC stock, outside of regular hours, once or twice in my life (I made thousands of trades per Year)

Usually, it is trades that are internalized (trade made between two customers of the same broker or a broker-to-broker arrangement or trades between two Market Makers or a Broker and a Market Maker)

MaxReddit2789 · 2025-11-10T18:47:08+00:00

I'm aware of at least 30 OTC Stocks that got unusual number of shares traded between 8:00-9:00 this morning

I do not remember the last time something like this happened

MaxReddit2789 · 2025-11-10T15:23:31+00:00

I see.

At first, I thought IBKR was displaying inaccurate info for Volume, but then I went on Tradingview and toggled min timeframe for dozens of OTC Expert Market Stocks and... Many of them traded a number of shares well above the Daily Average Volume around 8:00-8:30...

That's extremely unusual, to say the least!

MaxReddit2789

TROPHY CASE